At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 377 enrolled
Drug / intervention
Placebo +2 moredrug
Likely dose
dalfampridine-ER 7.5mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
This is a Multi-center, Double-blind, Three Arm, Parallel Group, Placebo-controlled, Randomized Study Designed to Evaluate the Efficacy, Safety and Tolerability of Dalfampridine.
In Brief
A Phase 3 clinical trial evaluating Placebo, dalfampridine-ER 7.5mg, and 1 other intervention for Post-Ischemic Stroke. Completed, enrolled 377 participants across 74 sites in 2 countries.
Detailed Summary
The objective of this study is to determine the effect of two dose strengths of dalfampridine-Extended Release (ER) tablets, taken twice daily for 12 weeks, on stable walking deficits in subjects with post-ischemic stroke.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost-Ischemic Stroke
CountriesCanada, United States
Collaborators--
Timeline
Phase 3CompletedFinished
201520162017201820192020202120222023202420252026
First PostedOct 2014
Enrollment StartDec 2014
Primary CompletionSep 2016
Study CompletionOct 2016
TodayJul 2026
First PostedOct 22, 2014
Enrollment StartDec 1, 2014
Primary CompletionSep 1, 2016
Study CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 11.7 years ago
Interventions
Placebodrug
dalfampridine-ER 7.5mgdrug
dalfampridine-ER 10mgdrug